Bristol-Myers Squibb and Five Prime Therapeutics announce exclusive clinical collaboration
Bristol-Myers and Five Prime Therapeutics announced an agreement to evaluate safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, with FPA008, Five Prime’s monoclonal antibody that inhibits CSF1R. November 24, 2014